These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14577496)

  • 1. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.
    Erdem E; Atsü N; Akbal C; Bilen CY; Ergen A; Ozen H
    Int Urol Nephrol; 2002; 34(4):519-23. PubMed ID: 14577496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.
    Bianco FJ; Wood DP; Cher ML; Powell IJ; Souza JW; Pontes JE
    Clin Prostate Cancer; 2003 Mar; 1(4):242-7. PubMed ID: 15040883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of sextant biopsies to predict radical prostatectomy stage.
    Wills ML; Sauvageot J; Partin AW; Gurganus R; Epstein JI
    Urology; 1998 May; 51(5):759-64. PubMed ID: 9610589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer.
    Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Id H'Mammed Y; de Torres IM
    Int J Biol Markers; 2002; 17(4):239-43. PubMed ID: 12521127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.